April 27, 2022
Basilea announces licensing of a novel first-in-class antifungal program from Fox Chase Chemical Diversity Center
Basilea Pharmaceutica Ltd has entered into a licensing agreement with the U.S.-based company, Fox Chase Chemical Diversity Center, Inc. (FCCDC), for a preclinical program on novel first-in-class broad spectrum antifungals with activity against difficult-to-treat mold infections.